Trinity Biotech announced that it has received additional purchase orders for over 2 million units of its rapid HIV test, TrinScreen™ HIV, and published its Q1 2026 financial results.

DUBLIN

Who

Trinity Biotech plc (Nasdaq: TRIB), John Gillard (CEO of Trinity Biotech)

What

When

Tue, 16 Jun 2026 13:18:42 GMT · 1h 30m ago

Where

DUBLIN ·

Why

The orders reinforce strong demand outlook in global health markets, following disruptions in 2025 due to changes affecting international aid funding structures, and support the company's 2026 revenue and profitability targets.

The Frontline Impact

How this affects you

The receipt of orders for over 2 million HIV tests and improved Q1 2026 financial results for Trinity Biotech plc indicate a resurgence in demand for rapid HIV diagnostics in global health markets, which could lead to increased access to testing in countries with high HIV prevalence. The company's Comprehensive Transformation Plan, including outsourced manufacturing, is contributing to significant gross margin improvements.

Story chain

1 event in this thread

No related history yet - this is the origin event.

Verified Sources & Citations

The Manila Times
https://www.manilatimes.net/2026/06/16/tmt-newswire/globenewswire/trinity-biotech-awarded-significant-orders-for-over-2-million-trinscreen-hiv-tests-and-reports-q1-2026-financial-results/2366711
HIGH

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.